← Back to Clinical Trials
Recruiting NCT01222741

NCT01222741 Studies of Disorders With Increased Susceptibility to Fungal Infections

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT01222741
Status Recruiting
Phase —
Sponsor National Institute of Allergy and Infectious Diseases (NIAID)
Condition Fungal Infections
Study Type OBSERVATIONAL
Enrollment 850 participants
Start Date 2011-01-07
Primary Completion —

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 85 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 850 participants in total. It began in 2011-01-07.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Background: \- Researchers are interested in studying disorders that make individuals more susceptible to fungal infections, specifically infections with the Candida yeast. These disorders are often related to problems with the immune system and may have genetic factors, which suggests that researchers should study not only the individual with the disorder, but also his or her first- and second-degree relatives (such as parents, siblings, children, and first cousins). To provide material for future research, individuals with immune disorders and their first- and second-degree relatives will be asked to provide blood and other samples for testing and comparison with samples taken from healthy volunteers with no history of immune disorders. Objectives: \- To collect blood and other biological samples to study immune disorders that make individuals more susceptible to fungal infections. Eligibility: * Individuals of any age who have abnormal immune function characterized by recurrent or unusual fungal infections, recurrent or chronic inflammation, or other types of immune dysfunction. * First- or second-degree genetically related family members (limited to mother, father, siblings, grandparents, children, aunts, uncles, and first cousins). * Healthy volunteers at least 18 years of age (for comparison purposes). Design: * Participants will provide blood samples and buccal (cells from the inside of the mouth near the cheek) samples. * Participants with immune disorders will also be asked to provide urine samples, saliva or mucosal samples, or skin tissue biopsies, and may also have imaging studies (such as x-rays) to collect information for research. * Samples may be collected at the National Institutes of Health or at other clinical locations for the samples to the sent to the National Institutes of Health. * No treatment will be provided as part of this protocol.

Eligibility Criteria

* INCLUSION CRITERIA: Patients To be eligible to participate in this study as a patient, an individual must meet the following criteria: * Be 2 years of age to be seen at the Clinical Center as an outpatient. Children \<=3 years of age must not have severe infections, as assessed by the investigator, to be seen at the Clinical Center. Send-in samples may be submitted by participants \>30 days of age. * Have an abnormality of immune function as manifested by recurrent or unusual fungal infections, recurrent or chronic inflammation, or previous laboratory evidence of immune dysfunction. Of particular focus of this study are patients with: * APECED * CMC * MPO * IPEX * Hyper-immunoglobulin E syndrome (Job s syndrome) * CGD * Biotinidase deficiency * IKAROS defects * AIOLOS defects * IRF4 defects * Other conditions showing increased susceptibility to such infections as described in infants and type 1 diabetic patients * Have a primary physician outside of the NIH. * Agree to have blood stored for future research. * Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document. Relatives To be eligible to participate in this study as a relative, an individual must meet the following criteria: * Be 2 years of age to be seen at the Clinical Center as an outpatient. Children \<=3 years of age must not have severe infections, as assessed by the investigator, to be seen at the Clinical Center. Send-in samples may be submitted for participants \>30 days of age. * Be a mother, father, sibling, child, grandparent, aunt, uncle, or first cousin to a patient participant. * Adult relatives must be able to provide informed consent. * Agree to have blood stored for future research. Healthy volunteers To be eligible to participate in this study as a healthy volunteer, an individual must meet the following criteria: * Be 18 to 85 years old. * Have a hemoglobin count of \>11 g/dL. * Weigh \>=110 pounds. * Be able to provide informed consent. * Be willing to have blood stored for future research. EXCLUSION CRITERIA: Patients and Relatives In general, there are no strict exclusion criteria for these cohorts. However, the presence of certain types of acquired abnormalities of immunity solely due to HIV, chemotherapeutic agent(s), or an underlying malignancy could be grounds for possible exclusion for a patient or relative. In the opinion of the investigator, the presence of such disease processes may interfere with evaluation of a co-existing abnormality of immunity that is the subject of study under this protocol. Pregnant females will not be allowed to participate in any procedure that may be dangerous to the pregnancy or the fetus. Healthy volunteers An individual who meets any of the following criteria will be excluded from participation as a healthy volunteer in this study: * Is receiving chemotherapeutic agent(s) or has an underlying malignancy. * Is pregnant. * Has a history of heart, lung, or kidney disease, or bleeding disorders. * Has HIV or viral hepatitis (B or C), or history of viral hepatitis B or C since age 11.

Contact & Investigator

Central Contact

Sergio D Rosenzweig, M.D.

✉ srosenzweig@mail.nih.gov

📞 (301) 451-8971

Principal Investigator

Sergio D Rosenzweig, M.D.

PRINCIPAL INVESTIGATOR

National Institute of Allergy and Infectious Diseases (NIAID)

Frequently Asked Questions

Who can join the NCT01222741 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Fungal Infections. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT01222741 currently recruiting?

Yes, NCT01222741 is actively recruiting participants. Contact the research team at srosenzweig@mail.nih.gov for enrollment information.

Where is the NCT01222741 trial being conducted?

This trial is being conducted at Bethesda, United States.

Who is sponsoring the NCT01222741 clinical trial?

NCT01222741 is sponsored by National Institute of Allergy and Infectious Diseases (NIAID). The principal investigator is Sergio D Rosenzweig, M.D. at National Institute of Allergy and Infectious Diseases (NIAID). The trial plans to enroll 850 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology